Page updated ·next FDA decision on the calendar·Data as of Oct 14, 2026 7:39 PM ET
Price into the decision (T-120)
Daily close, T-120 (8/15/24) through T+5. Run-up high $516.74 on 11/15/24, low $396.64 on 12/25/24 (T-120 to T-1). FDA decision 1/30/25. Historical price action, not a forecast.
Positioning before the decision
On Jan 16, 2025, 14 days before the decision date, at-the-money options priced a move of ±4.9% through Jan 31, 2025 (the first listed expiry after the decision; ATM implied volatility 30%). The stock closed -0.7% at the first close across the decision and +10.6% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Decision facts
FDA decision date2025-01-30
DrugSuzetrigine (VX-548)
IndicationAcute Pain following bunionectomy or abdominoplasty surgery
Every FDA approval letter and released Complete Response Letter we hold, by FDA action date: FDA approval letters.
Questions
Was Suzetrigine (VX-548) approved by the FDA?
Yes. The FDA approved the application for Suzetrigine (VX-548) on January 30, 2025, per the FDA's own record. The primary source is linked on this page.
What was Suzetrigine (VX-548) under FDA review for?
The application covered Acute Pain following bunionectomy or abdominoplasty surgery. The FDA approved the application on January 30, 2025.
How did VRTX stock react to the FDA decision?
On the decision day VRTX moved -0.7%. That is the recorded reaction to this specific event. Historical measurement, not a prediction, and not investment advice.